Niagen Bioscience, Inc. NAGE
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 122.29M | 129.08M | 130.42M | 129.42M | 124.71M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 122.29M | 129.08M | 130.42M | 129.42M | 124.71M |
| Cost of Revenue | 44.19M | 46.16M | 46.58M | 46.23M | 45.03M |
| Gross Profit | 78.10M | 82.92M | 83.83M | 83.19M | 79.68M |
| SG&A Expenses | 68.81M | 67.81M | 66.18M | 62.56M | 54.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 119.50M | 120.47M | 119.32M | 115.13M | 105.41M |
| Operating Income | 2.79M | 8.62M | 11.10M | 14.30M | 19.30M |
| Income Before Tax | 11.06M | 17.03M | 19.70M | 18.19M | 21.25M |
| Income Tax Expenses | 815.00K | 1.04M | 1.06M | 810.00K | 823.00K |
| Earnings from Continuing Operations | 10.24 | 15.99 | 18.64 | 17.38 | 20.43 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.24M | 15.99M | 18.64M | 17.38M | 20.43M |
| EBIT | 2.79M | 8.62M | 11.10M | 14.30M | 19.30M |
| EBITDA | 3.86M | 9.59M | 11.98M | 15.08M | 20.08M |
| EPS Basic | 0.13 | 0.20 | 0.23 | 0.22 | 0.26 |
| Normalized Basic EPS | 0.03 | 0.08 | 0.10 | 0.13 | 0.17 |
| EPS Diluted | 0.12 | 0.18 | 0.21 | 0.20 | 0.24 |
| Normalized Diluted EPS | 0.03 | 0.08 | 0.09 | 0.12 | 0.16 |
| Average Basic Shares Outstanding | 317.36M | 317.99M | 317.92M | 315.81M | 313.78M |
| Average Diluted Shares Outstanding | 330.66M | 338.13M | 341.87M | 340.54M | 337.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |